Trial Profile
Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2014
Price :
$35
*
At a glance
- Drugs Belinostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 19 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov (NCT01647009).
- 19 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov (NCT01647009).
- 19 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov (NCT01647009).